OIG Finds Distribution of UIP Funds Did Not Comply With Federal Requirements
- By Lee Fifield
- In Audit
- August 17, 2023
- Comments Off on OIG Finds Distribution of UIP Funds Did Not Comply With Federal Requirements
Uninsured program payments were made to providers for patients who had health insurance and for services unrelated to COVID-19.
In July 2023, the Office of Inspector General (OIG) released the results of its audit of the oversight and management of the COVID-19 Uninsured Program (UIP). The UIP was created as part of a series of bills passed by Congress which allowed eligible hospitals and other healthcare providers to submit claims for reimbursement of COVID-19 testing and treatment for uninsured individuals. The program was administered by the Health Resources and Services Administration (HRSA) under the U.S. Department of Health and Human Services (HHS).
The OIG’s audit objective was to determine whether claims reimbursed under the UIP complied with federal requirements.
How the Audit Was Conducted
The OIG’s audit covered claims for 19 million patients with associated UIP provider payments totaling $4.2 billion with service dates from March 1 through Dec. 31, 2020. HRSA officials and their contractor were interviewed, and health insurance coverage data, medical records, and billing records were analyzed. A stratified random sample of 300 patients with associated provider payments totaling $2.8 million was reviewed.
UIP Background
The HRSA used a contractor to help administer the UIP through an online portal. Providers who enrolled in the UIP submitted a patient roster which listed patients who received COVID-19 testing and treatment services and were determined by the provider to be uninsured. The contractor was then tasked with checking each patient’s insurance coverage eligibility against internal and external databases. The system was not foolproof, however, since providers were not required to submit a social security number (SSN) for each patient.
The HHS decided that providers would not be required to submit SSNs to ensure that a patient’s fear of providing their SSN (or their inability to do so) would not preclude the patient from receiving COVID-19 testing or treatment or the provider from receiving reimbursement for their claims. As a result, the HRSA’s contractor was unable to verify a patient’s health insurance eligibility through its internal and third-party databases when a SSN was not provided, and had to rely solely on the provider’s attestation that a patient’s health insurance eligibility had been checked and their uninsured status confirmed. As a result of this ineffective process, health insurance coverage status was not verified for the vast majority of patients for whom claims were reimbursed under the UIP.
Providers were also required to attest that they had read and agreed to UIP terms and conditions for testing and treatment services, including the UIP’s definitions of eligible services. The terms and conditions stated that UIP testing was eligible to be claimed for reimbursement for in vitro diagnostic tests for detecting SARS-CoV-2 or diagnosing the virus that causes COVID-19 and the administration of such tests. Furthermore, testing-related items and services were eligible to be claimed for reimbursement if provided to an individual during an office, telehealth, urgent care, or emergency room visit that resulted in an order for or administration of a COVID-19 test, but only to the extent that the items and services related to the test or an evaluation of the individual for the need of such a test. UIP treatment services were eligible to be claimed for reimbursement if a patient had a primary COVID-19 diagnosis and the services were for the care or treatment of COVID-19 and its complications.
The HRSA, however, did not provide guidance on UIP claim coding to providers. Rather, they provided billing guidelines to allow providers to identify and submit only claims eligible for reimbursement under the UIP. Consequently, for 22 of the 300 sampled patients, the HRSA made UIP payments for claims for COVID-19 services totaling $161,465 to providers for testing or treatment services that were not provided or were unrelated to COVID-19.
Audit Results
Of the 300-patient sample, 240 patients met UIP terms and conditions, seeing providers who had effective processes in place to ensure that they did not engage in balance billing or charge patients for cost-sharing. UIP payments for 58 patients totaling $294,294 were deemed improper because they were either made on behalf of patients who had health insurance coverage or were made for testing and treatment services that were not provided or were unrelated to COVID-19. (The OIG was unable to make a determination on the remaining two patients because their providers did not comply with requests for further documentation.)
Extrapolating from this patient sample, the OIG estimates that nearly $784 million of the $4.2 billion (19 percent) of UIP payments made to providers were improper.
OIG Recommendations
The OIG recommended that the HRSA:
- Recover the $294,294 in improper UIP payments identified in the sample;
- Identify additional improper UIP payments for services provided to insured individuals or services unrelated to COVID-19, estimated to be $783.6 million, and take remedial action; and
- Commit to strengthening its procedures that may apply to future programs of a similar nature.
An Eye to the Future
The OIG recognized that the HRSA’s operational objective at the beginning of the national emergency was to rapidly disburse funds for COVID-19 testing and treatment to ensure uninsured individuals were receiving vital healthcare services and to prevent the spread of COVID-19. Unfortunately, the HRSA established procedures with its contractor that were not effective at ensuring that the UIP only reimbursed eligible claims. The OIG recommended that any agency setting up and administering similar programs in the future consider the information in this audit report as an aid.
Resource:
https://oig.hhs.gov/oas/reports/region2/22101013.pdf
- CMS Issues 2027 ESRD Prospective Payment System Final Rule - November 5, 2026
- I Am AAPC: Diane Costa, CPC, CPCO, CPMA, CRC - November 2, 2026
- Expanding Electronic Prior Authorization for Self-Funded Health Plans - October 30, 2026


